Remdesivir and standard care showed no clear difference in serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).
Bamlanivimab showed no clear difference in adverse events: grades 3 and 4 by day 30 compared with placebo (low certainty).
The review found no eligible studies for this question.
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.
Blue light showed no clear difference in any adverse events (up to 90 days; MCID 5%) compared with white light (low certainty).
Hyperimmune immunoglobulin from human plasma probably leads to higher adverse events at grades 3 to 4 up to 28 days compared with saline placebo (moderate certainty).
Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in adverse events Number of participants reporting ≥ 1 serious adverse… compared with placebo (moderate certainty).
Clobetasol propionate cream may leads to lower adverse events: severe complications at day 21 compared with oral prednisone (low certainty).
Morning bright light showed no clear difference in adverse events (frequency) compared with afternoon bright light (low certainty).
Antibiotics showed no clear difference in serious adverse events Duration 3 days to 3 weeks compared with placebo or usual care (low certainty).
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
Three doses HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with control (high certainty).
Nonavalent HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with quadrivalent HPV vaccine (high certainty).